Revenues, Recognition and Allowances (Tables)

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenues

Net Sales (in thousands)

for the three and nine months ended September 30, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption):

	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Company product sales	$	16,375	$	9,436	$	44,288	$	37,556
Contract manufacturing sales	1,878		1,883		4,626		7,707
Research and development services and other income	41		21		$	174	$	172
Revenue, net	$	18,294	$	11,340	$	49,088	$	45,435

Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations, and is presented below according to contract type (in thousands):

	Three months ended September 30,				Nine months ended September 30,
Company Product Sales	2018		2017		2018		2017
Topical	$	10,503	$	5,913	$	26,297	$	22,066
Injectables	5,872		3,523		17,991		15,490
Total	$	16,375	$	9,436	$	44,288	$	37,556

Schedule of Accounts, Notes, Loans and Financing Receivable

The Company's adjustments for the deductions to gross product sales are as follows (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Gross product sales	$	40,111	$	53,460	$	124,801	$	174,504
Deduction to gross product sales:
Chargebacks and billbacks	10,739		30,954		49,103		105,059
Wholesaler fees for service	1,662		1,511		2,774		5,715
Sales discounts and other allowances	11,335		11,559		28,636		26,174
Total reduction to gross product sales	$	23,736	$	44,024	$	80,513	$	136,948
Company product sales, net	$	16,375	$	9,436	$	44,288	$	37,556